These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35053417)

  • 21. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
    Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S
    Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
    Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
    J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic peptide-selenium nanoparticles as drug transporters.
    Nasrolahi Shirazi A; Tiwari RK; Oh D; Sullivan B; Kumar A; Beni YA; Parang K
    Mol Pharm; 2014 Oct; 11(10):3631-41. PubMed ID: 25184366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
    Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
    Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
    Ryu JS; Kratz F; Raucher D
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
    Sheng Y; You Y; Chen Y
    Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.
    Ai S; Jia T; Ai W; Duan J; Liu Y; Chen J; Liu X; Yang F; Tian Y; Huang Z
    Br J Pharmacol; 2013 Apr; 168(7):1719-35. PubMed ID: 23146125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
    Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine.
    Nasrolahi Shirazi A; Tiwari RK; Oh D; Banerjee A; Yadav A; Parang K
    Mol Pharm; 2013 May; 10(5):2008-20. PubMed ID: 23537165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
    Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
    Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Molecular Transporter Efficiency of Cyclic Peptides Containing Tryptophan and Arginine Residues.
    Hanna SE; Mozaffari S; Tiwari RK; Parang K
    ACS Omega; 2018 Nov; 3(11):16281-16291. PubMed ID: 31458264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters.
    Nasrolahi Shirazi A; Oh D; Tiwari RK; Sullivan B; Gupta A; Bothun GD; Parang K
    Mol Pharm; 2013 Dec; 10(12):4717-27. PubMed ID: 24215132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracellular trafficking and cytotoxicity of a gelatine-doxorubicin conjugate in two breast cancer cell lines.
    Alvi MM; Nicoletto RE; Eshmawi BA; Kim HK; Cammarata CR; Ofner CM
    J Drug Target; 2020 Jun; 28(5):487-499. PubMed ID: 31601131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
    Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
    J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circumventing Doxorubicin Resistance Using Elastin-like Polypeptide Biopolymer-Mediated Drug Delivery.
    Dragojevic S; Turner L; Raucher D
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model.
    Gou Y; Zhang Z; Li D; Zhao L; Cai M; Sun Z; Li Y; Zhang Y; Khan H; Sun H; Wang T; Liang H; Yang F
    Drug Deliv; 2018 Nov; 25(1):321-329. PubMed ID: 29350051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
    Joshi M; Choi JS; Park JW; Doh KO
    J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms.
    Lei T; Srinivasan S; Tang Y; Manchanda R; Nagesetti A; Fernandez-Fernandez A; McGoron AJ
    Nanomedicine; 2011 Jun; 7(3):324-32. PubMed ID: 21094277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil
    Cagel M; Bernabeu E; Gonzalez L; Lagomarsino E; Zubillaga M; Moretton MA; Chiappetta DA
    Biomed Pharmacother; 2017 Nov; 95():894-903. PubMed ID: 28903185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.